论文部分内容阅读
目的探讨中期引产联合用药的最佳疗效。方法孕14～26周妊娠患者,用利凡诺尔100mg羊膜腔内注药,同时口服米非司酮片75mg,每日2次,第2天分次口服米索前列醇片共600μg。结果引产成功的时间:A组单用利凡诺尔宫缩开始时间(34.7±3.4)h,引产成功时间为(43.5±3.5)h;而B组联合用药宫缩开始时间(24.8±2.1)h,引产成功时间(30.0±2.8)h。B组明显优于A组,差异有统计学意义(P<0.01)。A组引产过程腹痛严重,非常痛苦,而B组联合用药一般能忍受,痛苦小,差异有统计学意义(P<0.01)。产后出血A组<80ml占37.04%,B组占54.63%。≥120ml,A组占11.11%,B组占4.63%。结论中期引产联合用利凡诺尔+米非司酮+米索前列醇,引产成功时间短,出血量少,痛苦小,宫腔操作次数少,减少子宫内感染机会,值得推广。
Objective To explore the best curative effect of mid-term induction of labor. Methods Pregnant women aged 14 ~ 26 weeks pregnant with rivanol 100mg intra-amniotic injection, while oral mifepristone tablets 75mg, 2 times a day, the first two days of oral misoprostol tablets were 600μg. Results The successful time of induction of labor was as follows: In group A, the initiation time of ribavirin alone was (34.7 ± 3.4) h and that of labor was (43.5 ± 3.5) h, while that in group B was (24.8 ± 2.1) h , Successful induction of labor (30.0 ± 2.8) h. B group was significantly better than A group, the difference was statistically significant (P <0.01). In group A, abortion was severe and painful. However, combination therapy in group B was generally tolerable with little pain and the difference was statistically significant (P <0.01). Postpartum hemorrhage A group <80ml accounted for 37.04%, B group accounted for 54.63%. ≥120ml, A group accounted for 11.11%, B group accounted for 4.63%. Conclusions Mid-term induction of labor combined rivanol + mifepristone plus misoprostol, induction of labor short success time, less bleeding, less pain, less intrauterine operation, reduce the chance of intrauterine infection, it is worth promoting.